{"filings":[{"id":833959,"accession_number":"0001193125-26-255467","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-06-03T20:15:15+00:00","items":["1.01"],"status":"ready","headline":"CytomX and Regeneron expand collaboration; CytomX to receive $37M in target nomination payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 4 adds up to eight new collaboration programs; Regeneron nominates first two.","CytomX receives $37M aggregate target nomination payments for the two nominated programs.","Total potential milestones under expanded agreement are up to approximately $4 billion.","Royalty rates on global net sales unchanged; program selection period extended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93240,"accession_number":"0001193125-26-211920","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.","Cash $346.7M (Dec 31: $137.1M) includes $234.2M net from March equity offering; runway to at least 2H 2028.","Varseta-M dose optimization enrollment completed (40 patients); data update in 2H 2026 to inform monotherapy dose and potential registrational trial in late-line CRC.","Varseta-M + bevacizumab Phase 1 combo underway; initial data by 1H 2027; Phase 1/2 chemo combo starts 2H 2026.","CX-801 (PROBODY IFNα2b) Phase 1 combo with Keytruda enrolling third dose level; initial combo data expected end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10258000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104685,"accession_number":"0001193125-26-115958","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytomX closes public offering of ~47M shares/warrants, net proceeds ~$234.4M for pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 45,990,567 shares at $5.30 and pre-funded warrants for 1,179,245 shares at $5.29999 each.","Underwriters granted 30-day option to purchase up to 7,075,471 additional shares at the offering price.","Net proceeds estimated at approximately $234.4 million after underwriting discounts and expenses.","Proceeds to fund continued development of Varseta-M and other pipeline programs, plus general corporate purposes.","Offering closed on March 19, 2026 under an underwriting agreement dated March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104684,"accession_number":"0001193125-26-107152","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.","Cash and investments $137.1M at Dec 31, 2025, up from $100.6M; cash runway to Q2 2027.","Astellas terminated preclinical alliance effective Q2 2026; research with BMS, Amgen, Regeneron, Moderna continues.","Varseta-M Phase 1 data positive; FDA alignment for potential registrational trial in late-line CRC targeted mid-2026.","CX-801 Phase 1 combo with KEYTRUDA in melanoma initial proof-of-concept data expected by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120985,"accession_number":"0001193125-25-269533","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.","R&D expenses $15.3M (-$6.1M YoY); G&A $6.4M (-$1.5M YoY); total operating expense $21.7M.","CX-2051 Phase 1 enrollment ~100 patients by Q1 2026 data update; Phase 1b combo with bevacizumab starts Q1 2026.","CX-801 Phase 1 monotherapy biomarker data at SITC 2025; combo with KEYTRUDA dose escalation enrolling 2nd dose level.","Appointed Rachael Lester as SVP, Chief Business Officer in October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":75538000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137586,"accession_number":"0001193125-25-179463","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.","Safety Review Committee convened July 14, 2025, supported continued study execution and enrollment.","FDA notified on July 18, 2025; company aware on July 11, 2025.","CX-2051 dose expansions at 7.2, 8.6, and 10 mg/kg each enrolled ~20 patients as planned.","Phase 1 data update expected by Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137585,"accession_number":"0000950170-25-105053","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.","Cash, equivalents and investments $158.1M at June 30, 2025, up from $79.9M on March 31, 2025; cash runway to Q2 2027.","Positive interim data from CX-2051 Phase 1 in advanced colorectal cancer; dose expansions initiated at 7.2, 8.6, 10 mg/kg Q3W.","CX-2051 Phase 1 data update on ~70 patients by Q1 2026; Phase 2 study in late-line CRC expected in 1H 2026.","Completed $100M underwritten offering, net proceeds $93.4M; CX-801 plus KEYTRUDA dose escalation started for advanced melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":69575000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154954,"accession_number":"0001193125-25-140739","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CytomX stockholders approve amended equity plan adding 4.38M shares; three directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected three Class I directors: Sean McCarthy (16.4M for), Mani Mohindru (19.7M for), Zhen Su (19.7M for), terms until 2028.","Amended 2015 Equity Plan approved; shares available increase to 6,300,000 from prior pool plus 4,381,320 new shares.","Employee Stock Purchase Plan amended to remove evergreen automatic increase and remove 10-year expiration, now indefinite.","Ratified Ernst & Young as auditor for FY2025; advisory vote on exec compensation approved with ~22.9M for, 5.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154953,"accession_number":"0001193125-25-129470","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytomX regains Nasdaq minimum bid price compliance as of May 23, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff notified company on May 27, 2025, of compliance regained.","Closing price ≥ $1.00 for 10 consecutive trading days ended May 23, 2025.","Resolves previous deficiency notice from February 24, 2025.","Matter is now closed with no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154952,"accession_number":"0001193125-25-118805","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytomX nets $93.4M in underwritten common stock offering; 76.9M shares at $1.30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 76,923,076 shares of common stock at $1.30/share, generating ~$93.4M in net proceeds after underwriting discounts and expenses.","Proceeds to be used for research and development, general corporate purposes, and working capital.","Underwriting syndicate led by Jefferies and Piper Sandler & Co.","Offering closed on May 13, 2025; shares issued under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154951,"accession_number":"0001193125-25-117245","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.","CX-2051 Phase 1: 28% ORR (5/18 confirmed PRs), 94% DCR, median PFS 5.8 months in advanced CRC.","Dose expansions started at 7.2, 8.6, 10 mg/kg Q3W; Phase 2 planned 1H 2026.","Astellas milestone $5M; cash runway into Q2 2026.","CX-801 Phase 1a data in melanoma expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":50917000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173464,"accession_number":"0000950170-25-034585","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Therapeutics 2024 revenue $138.1M (up 36% YoY); CX-2051 data expected 1H 2025; headcount cut 40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.","Lead program CX-2051 (EpCAM ADC) Phase 1a initial data in advanced CRC expected 1H 2025; dose escalation at 7th dose level.","CX-801 (IFN-alpha) Phase 1a translational data in melanoma expected 2H 2025; monotherapy dose exceeds approved peginterferon dose.","CX-904 (EGFR-CD3 TCE) development discontinued by mutual decision with Amgen.","January 2025 restructuring reduced headcount ~40% to extend cash runway into Q2 2026; Astellas milestone triggered $5M payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173463,"accession_number":"0001193125-25-036794","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CytomX receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CytomX on Feb 24, 2025 that common stock bid price stayed below $1.00 for 30 consecutive business days through Feb 21, 2025.","Company has 180 calendar days, until August 25, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.","If not cured by the deadline, CytomX may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","Company will monitor bid price and consider options, but there is no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173462,"accession_number":"0001193125-25-019257","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX CBO Jeffrey Landau to depart effective Feb 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Landau, SVP, Chief Business Officer, and Head of Strategy, will leave the company on February 7, 2025.","Separation agreement provides economic payments consistent with existing severance and change of control agreement.","Separation includes a general release of claims against the company.","No replacement for Landau's role has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173461,"accession_number":"0001193125-25-002165","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.","Estimated restructuring charges of $5M to $6M, mostly severance, recorded in Q1 2025.","Cash payments of ~$5M starting Q1 2025; cash runway extended into Q2 2026.","Company to prioritize CX-2051 (EpCAM PROBODY ADC) and support research collaborations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190452,"accession_number":"0000950170-24-123314","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q3 revenue $33.4M (up 26% YoY); cash $117.6M; pipeline programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.4M in Q3 2024, up from $26.4M in Q3 2023 (+26.5%).","Cash & investments $117.6M as of Sep 30, 2024 (down from $137.2M at June 30); runway to end of 2025.","CX-904 Phase 1a cleared 15 mg dose; Phase 1b possible in 2025 pending dose/schedule optimization.","CX-2051 Phase 1a in colorectal cancer in fifth dose cohort; initial data expected H1 2025.","CX-801 Phase 1a started, first patient dosed; initial data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":100010000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206952,"accession_number":"0000950170-24-093936","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.","Total revenue $25.1M in Q2 2024, up from $24.7M in Q2 2023; R&D expense $25.2M incl. $5M milestone to AbbVie.","CX-904 (EGFRxCD3) Phase 1a enrollment continues in PDAC, NSCLC, HNSCC; program update expected by end of 2024.","CX-2051 (EpCAM ADC) Phase 1 dose escalation in third cohort; initial data expected in first half of 2025.","CX-801 (IFNα2b cytokine) first clinical site active; initial data expected in 2025; $10M Astellas milestones achieved YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":66578000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224240,"accession_number":"0001193125-24-162652","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.","Ogden continues as Principal Accounting and Financial Officer, roles held since September 2022.","Granted option to purchase 75,000 shares and RSU award for 17,500 shares under 2015 Equity Incentive Plan.","No family relationships or arrangements with other parties in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224239,"accession_number":"0001193125-24-141699","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Stockholders approve doubling authorized common stock to 300M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Charter amendment to increase authorized common stock from 150M to 300M shares approved with 42.7M for, 3.2M against.","Class III directors Ashworth, Meyers, and Gilbert each elected with >24M votes for; broker non-votes of 17.6M.","Ratification of Ernst & Young as auditor for FY2024 passed with 46.5M votes for.","Advisory vote on executive compensation approved with 27.4M for, 1.9M against, 17.6M broker non-votes.","All four stockholder proposals at May 15 Annual Meeting were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224238,"accession_number":"0001193125-24-134284","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.","In 6 efficacy-evaluable pancreatic cancer patients, 2 confirmed partial responses (33%) and all 6 had disease control.","One patient achieved 83% tumor reduction at 6 mg; another 51% at 5 mg; both remained on treatment.","Preliminary PK/PD data support PROBODY T-cell engager mechanism: maintained masking and CD8+ T-cell margination.","Dose escalation continues; Phase 1b expansion in EGFR-positive tumors planned with partner Amgen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224237,"accession_number":"0000950170-24-055598","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.","CX-904 (EGFRxCD3) shows favorable safety; 2 of 6 pancreatic patients with confirmed partial responses.","CX-2051 (EpCAM ADC) first patient dosed Apr 2024; first dose cohort cleared; initial data H1 2025.","CX-801 (IFNα2b) to start Phase 1 in Q2 2024; collaboration with Merck for KEYTRUDA combo.","Achieved $10M in Astellas milestones for two T-cell engager programs; Dr. Zhen Su appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":41463000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243583,"accession_number":"0001193125-24-075211","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"CytomX appoints Zhen Su to Board; adopts amended bylaws for stockholder proposals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zhen Su, M.D., M.B.A., appointed to Board as Class I director effective March 20, 2024, filling a vacancy.","Dr. Su receives standard non-employee director compensation and an option to purchase 76,000 shares vesting over three years.","Board adopted Amended and Restated Bylaws to modernize stockholder nomination and proposal procedures, including removal of 'acting in concert' provisions.","Bylaw amendments effective immediately with clarifying and technical changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243582,"accession_number":"0000950170-24-029207","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX FY2023 revenue $101.2M, operating expenses down 30%; BMS discontinues 986288, CX-904 data H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).","Cash $174.5M at Dec 31, 2023 vs $193.7M a year earlier; includes $30M from July 2023 BVF financing.","BMS notified CytomX it will not continue BMS-986288 beyond current Phase 2; research collaboration with multiple TCE programs continues.","CX-904 EGFRxCD3 Phase 1a data expected H2 2024; CX-2051 and CX-801 Phase 1 starts H1 2024 after IND clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}